Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole in spinocerebellar ataxia type 7
2018-000282-37Phase 2Active
- Sponsor
- Nesmos
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Placebo-COD Research Private Ltd in spinocerebellar ataxia type 7 (SCA7) (2 arms), sponsored by Nesmos. Primary endpoint: Proportion of patients with stable SARA score and visual acuity at 18 months. Started Jun 2021; status: active.
02
Drugs
Placebo-COD Research Private Ltd
03
Conditions
spinocerebellar ataxia type 7 (SCA7)
Beyond the preview
Go deeper on 2018-000282-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000282-37.